John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 milestones ahead of its participation in the 43rd Annual J.P. Morgan ...

Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 43rd Annual ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Correcting & Replacing: Y-mAbs Therapeutics, Inc. is re-issuing in entirety its press release, originally issued on January 10, 2025 at 7:05 a.m. ET, to correct a scrivener's error in the presentation ...

Winning with a top-flight investment framework. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a ...

Tony Lee joined the value team in 2018; he covers healthcare, insurance ... who average 22 years of industry experience. J.P. Morgan is a well-resourced, diligent, and responsible steward of ...